Drug intelligence / Profile preview

GC3110B

Development stage: Phase 3
Lead developer: 绿十字
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**GC3110B** is an investigational quadrivalent, inactivated influenza vaccine developed by GC Biopharma for prevention of seasonal human influenza. The vaccine contains purified inactivated influenza-virus antigens representing four influenza strains and is administered by intramuscular injection. It was evaluated against GCFLU Quadrivalent Inj. in a randomized, double-blind, multicenter Phase 3 immunogenicity and safety study in healthy adults aged 18 to 60 years. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02915809))

Other names: GC3110B vaccineGC-3110B vaccineGC 3110B vaccine

Targets

NeuraminidaseHA (Hemagglutinin)

Beyond the preview

Go deeper on GC3110B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC3110B.

Explore the full profile